Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials -- XENE shares fell as much as 27.6%. NEW YORK, Sept. 22, 2026 /PRNewswire/ -- A roughly...